Statin therapy and outcome after ischemic stroke: Systematic review and meta-analysis of observational studies and randomized trials

Stroke

Volumn 44, Issue 2, 2013, Pages 448-456

  Ní Chróinín, Danielle ^a   Asplund, Kjell ^b,c   Åsberg, Signild ^d   Callaly, Elizabeth ^a   Cuadrado Godia, Elisa ^d   Díez Tejedor, Exuperio ^e   Di Napoli, Mario ^f,g   Engelter, Stefan T ^h   Furie, Karen L ⁱ   Giannopoulos, Sotirios ^j   Gotto, Antonio M ^k   Hannon, Niamh ^a   Jonsson, Fredrik ^b,c   Kapral, Moira K ^l   Martí Fàbregas, Joan ^m   Martínez Sánchez, Patricia ^e   Milionis, Haralampos J ^j   Montaner, Joan ^b,n   Muscari, Antonio ^o   Pikija, Slaven ^p   Probstfield, Jeffrey ^q   Rost, Natalia S ⁱ   Thrift, Amanda G ^r,s   Vemmos, Konstantinos ^t   Kelly, Peter J ^a   more..

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d HOSPITAL DEL MAR   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

^g SMDN   (Italy)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j UNIVERSITY OF IOANNINA   (Greece)

^k WEILL CORNELL MEDICAL COLLEGE   (United States)

^l TORONTO GENERAL HOSPITAL   (Canada)

^m HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁿ UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^o UNIVERSITY OF BOLOGNA   (Italy)

^p Varazdin General Hospital   (Croatia)

^q UNIVERSITY OF WASHINGTON   (United States)

^r MONASH MEDICAL CENTRE   (Australia)

^s FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^t UNIVERSITY OF ATHENS   (Greece)

more..

Author keywords

cerebral infarction; ischemia; neuroprotective agents; outcomes assessment; stroke; therapy

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

BLOOD CLOT LYSIS; BRAIN ISCHEMIA; FOLLOW UP; HUMAN; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANKIN SCALE; REVIEW; SURVIVAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

BRAIN ISCHEMIA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 84872929861     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.668277     Document Type: Review

References (74)

1. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Eng J Med. 355: 549-559
2. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004;35:2902-2909.
3. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267-1278
4. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
5. Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke. 2001;32:980-986.
6. Asahi M, Huang Z, Thomas S, Yoshimura S, Sumii T, Mori T, et al. Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J Cereb Blood Flow Metab. 2005;25:722-729.
7. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 1998;95:8880-8885.
8. Kawashima S, Yamashita T, Miwa Y, Ozaki M, Namiki M, Hirase T, et al. HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke. 2003;34:157-163.
9. Sironi L, Cimino M, Guerrini U, Calvio AM, Lodetti B, Asdente M, et al. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler Thromb Vasc Biol. 2003;23:322-327.
10. Chen J, Zhang ZG, Li Y, Wang Y, Wang L, Jiang H, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol. 2003;53:743-751.
11. Di Napoli P, Taccardi AA, Oliver M, De Caterina R. Statins and stroke: evidence for cholesterol-independent effects. Eur Heart J. 2002;23:1908-1921.
12. Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke. 1999;30:1969-1973.
13. Cakmak A, Yemişci M, Koksoy C, Yazgan U, Dincer D, Dalkara T. Statin pre-treatment protects brain against focal cerebral ischemia in diabetic mice. J Surg Res. 2007;138:254-258.
14. Laufs U, Gertz K, Dirnagl U, Bohm M, Nickenig G, Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res. 2002;942:23-30.
15. Arboix A, Garcia-Eroles L, Oliveres M, Targa C, Balcells M, Massons J. Pretreatment with statins improves early outcome in patients with firstever ischaemic stroke: a pleiotropic effect of statins or a beneficial effect of hypercholesterolemia? BMC Neurol. 2010;10:47.
16. Aslanyan S, Weir CJ, McInnes GT, Reid JL, Walters MR, Lees KR. Statin administration prior to ischaemic stroke onset and survival: exploratory evidence from matched treatment-control study. Eur J Neurol. 2005;12:493-498.
17. Biffi A, Devan WJ, Anderson CD, Cortellini L, Furie KL, Rosand J, et al. Statin treatment and functional outcome after ischemic stroke: casecontrol and meta-analysis. Stroke. 2011;42:1314-1319.
18. Cho Y-J, Gyeonnggi G, Khoury J, Kleindorfer D, Khatri P, Flaherty M, et al. Pretreatment with HMG-CoA reductase inhibitors reduces mortality after ischemic stroke in a population-based setting: results from the Greater Cincinnati/Northern Kentucky Stroke Study. Neurology. 2006; 66 (Suppl 2): A190, S26.005
19. Elkind MS, Flint AC, Sciacca RR, Sacco RL. Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality. Neurology. 2005;65:253-258.
20. Hassan Y, Al-Jabi SW, Aziz NA, Looi I, Zyoud SH. Statin use prior to ischemic stroke onset is associated with decreased in-hospital mortality. Fundam Clin Pharmacol. 2011;25:388-394.
21. Marti-Fabregas J, Gomis M, Arboix A, Aleu A, Pagonabarraga J, Belvis R, et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke. 2004;35:1117-1121.
22. Martinez-Sanchez P, Rivera-Ordonez C, Fuentes B, Ortega-Casarrubios MA, Idrovo L, Diez-Tejedor E. The beneficial effect of statins treatment by stroke subtype. Eur J Neurol. 2009;16:127-133.
23. Montaner J, Chacon P, Krupinski J, Rubio F, Millan M, Molina CA, et al. Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Eur J Neurol. 2008;15:82-90.
24. Moonis M, Kane K, Schwiderski U, Sandage BW, Fisher M. HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke. 2005;36:1298-1300.
25. Ni Chroinin D, Callaly EL, Duggan J, Merwick A, Hannon N, Sheehan O, et al. Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke: the North Dublin Population Stroke Study. Stroke. 2011;42:1021-1029.
26. Reeves MJ, Gargano JW, Luo Z, Mullard AJ, Jacobs BS, Majid A; Paul Coverdell National Acute Stroke Registry Michigan Prototype Investigators. Effect of pretreatment with statins on ischemic stroke outcomes. Stroke. 2008;39:1779-1785.
27. Stead LG, Vaidyanathan L, Kumar G, Bellolio MF, Brown RD Jr, Suravaram S, et al. Statins in ischemic stroke: just low-density lipoprotein lowering or more? J Stroke.Cerebrovasc Dis. 2009;18: 124-127.
28. Yoon SS, Dambrosia J, Chalela J, Ezzeddine M, Warach S, Haymore J, et al. Rising statin use and effect on ischemic stroke outcome. BMC Med. 2004;2:4.
29. Shook SJ, Gupta R, Vora NA, Tievsky AL, Katzan I, Krieger DW. Statin use is independently associated with smaller infarct volume in nonlacunar MCA territory stroke. J Neuroimaging. 2006;16:341-346.
30. Nicholas JS, Swearingen CJ, Thomas JC, Rumboldt Z, Tumminello P, Patel SJ. The effect of statin pretreatment on infarct volume in ischemic stroke. Neuroepidemiology. 2008;31:48-56.
31. Goldstein LB, Amarenco P, Zivin J, Messig M, Altafullah I, Callahan A, et al.; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2009;40:3526-3531.
32. Brea D, Blanco M, Ramos-Cabrer P, Moldes O, Arias S, Perez- Mato M, et al. Toll-like receptors 2 and 4 in ischemic stroke: outcome and therapeutic values. J Cereb Blood Flow Metab. 2011;31: 1424-1431.
33. Bushnell CD, Griffin J, Newby LK, Goldstein LB, Mahaffey KW, Graffagnino CA, et al. Statin use and sex-specific stroke outcomes in patients with vascular disease. Stroke. 2006;37:1427-1431.
34. Muscari A, Puddu GM, Santoro N, Serafini C, Cenni A, Rossi V, et al. The atorvastatin during ischemic stroke study: a pilot randomized controlled trial. Clin Neuropharmacol. 2011;34:141-147.
35. Ois A, Cuadrado-Godia E, Jimenez-Conde J, Gomis M, Rodriguez- Campello A, Martinez-Rodriguez JE, et al. Early arterial study in the prediction of mortality after acute ischemic stroke. Stroke. 2007;38:2085-2089.
36. Squizzato A, Romualdi E, Dentali F, Ageno W. Statins for acute ischemic stroke. Cochrane Database of Systematic Reviews 2011; Issue 8: Art. No.: CD007551. DOI: 10.1002/14651858.CD007551.pub2
37. Cappellari M, Deluca C, Tinazzi M, Tomelleri G, Carletti M, Fiaschi A, et al. Does statin in the acute phase of ischemic stroke improve outcome after intravenous thrombolysis? A retrospective study. J Neurol Sci. 2011;308:128-134.
38. Engelter ST, Soinne L, Ringleb P, Sarikaya H, Bordet R, Berrouschot J, et al. IV thrombolysis and statins. Neurology. 2011;77:888-895.
39. Miedema I, Uyttenboogaart M, Koopman K, De Keyser J, Luijckx GJ. Statin use and functional outcome after tissue plasminogen activator treatment in acute ischaemic stroke. Cerebrovasc Dis. 2010;29:263-267.
40. Alvarez-Sabin J, Huertas R, Quintana M, Rubiera M, Delgado P, Ribo M, et al. Prior statin use may be associated with improved stroke outcome after tissue plasminogen activator. Stroke. 2007;38:1076-1078.
41. Putaala J, Sairanen T, Meretoja A, Lindsberg PJ, Tiainen M, Liebkind R, et al. Post-thrombolytic hyperglycemia and 3-month outcome in acute ischemic stroke. Cerebrovasc Dis. 2011;31:83-92.
42. Uyttenboogaart M, Koch MW, Koopman K, Vroomen PC, Luijckx GJ, De Keyser J. Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke. J Neurol. 2008;255:875-880.
43. Martinez-Ramirez S, Delgado-Mederos R, Marin R, Suarez-Calvet M, Sainz MP, Alejaldre A, et al. Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke: results from a case-control study and a meta-analysis. J Neurol. 2012;259:111-118.
44. Segura T, Freijo M, Bravo Anguiano Y, Flores JM, Martinez-Zabeleta M, Garcia JT, et al (Principal Investigators). Stroke Treatment with Acute Reperfusion and Simvastatin (STARS) (NCT01073007). Accessed 05.03.12 from: http://www.strokecenter.org/trials/clinicalstudies/ stroke-treatment-with-acute- reperfusion-and-simvastatin-2
45. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
46. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for Meta-Analysis in Medical Research. I Ed. Chichester, UK: John Wiley & Sons;2000:39
47. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care- the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA.2002;288:2998-3007
48. Asberg S, Henriksson KM, Farahmand B, Asplund K, Norrving B, Appelros P, et al. Ischemic stroke and secondary prevention in clinical practice: a cohort study of 14,529 patients in the Swedish Stroke Register. Stroke. 2010;41:1338-1342.
49. Chitravas N, Dewey HM, Nicol MB, Harding DL, Pearce DC, Thrift AG. Is prestroke use of angiotensin-converting enzyme inhibitors associated with better outcome? Neurology. 2007;68:1687-1693.
50. Pikija S, Cvetko D, Hajduk M, Trkulja V. Higher mean platelet volume determined shortly after the symptom onset in acute ischemic stroke patients is associated with a larger infarct volume on CT brain scans and with worse clinical outcome. Clin Neurol Neurosurg. 2009;111:568-573.
51. Di Napoli M, Papa F. Inflammation, statins, and outcome after ischemic stroke. Stroke. 2001;32:2446-2447.
52. Cuadrado-Godia E, Jimenez-Conde J, Ois A, Rodriguez-Campello A, Garcia-Ramallo E, Roquer J. Sex differences in the prognostic value of the lipid profile after the first ischemic stroke. J Neurol. 2009;256:989-995.
53. Milionis HJ, Giannopoulos S, Kosmidou M, Panoulas V, Manios E, Kyritsis AP, et al. Statin therapy after first stroke reduces 10-year stroke recurrence and improves survival. Neurology. 2009;72:1816-1822.
54. Pikija S, Cvetko D, Malojčić B, Trkanjec Z, Pavliček I, Lukić A, et al. A population-based prospective 24-month study of stroke: incidence and 30-day case-fatality rates of first-ever strokes in Croatia. Neuroepidemiology. 2012;38:164-171.
55. Blanco M, Nombela F, Castellanos M, Rodriguez-Yanez M, Garcia-Gil M, Leira R, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomised study. Neurology. 2008; 70: 1720-1721
56. Kurzepa J, Bielewicz J, Bartosik-Psujek H, Szczepańska-Szerej A, Stelmasiak Z. Simvastatin inhibits the increase in serum tau protein levels in the acute phase of ischemic stroke. Pharmacol Rep. 2008;60:1014-1018.
57. Murakami M, Fujioka S, Hirata Y, Kuratsu J. Low-dose of statin treatment improves cerebrovascular reactivity in patients with ischemic stroke: single photon emission computed tomography analysis. J Stroke. Cerebrovasc Dis. 2008;17:16-22.
58. Ovbiagele B, Saver JL, Starkman S, Kim D, Ali LK, Jahan R, et al. Statin enhancement of collateralization in acute stroke. Neurology. 2007;68:2129-2131.
59. Beer C, Blacker D, Bynevelt M, Hankey GJ, Puddey IB. A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan. Int J Stroke. 2012;7:104-111.
60. Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, Sutton AJ, et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med. 2009;169:1658-1667.
61. Biffi A, Devan WJ, Anderson CD, Ayres AM, Schwab K, Cortellini L, et al. Statin use and outcome after intracerebral hemorrhage: case-control study and meta-analysis. Neurology. 2011;76:1581-1588.
62. Herrington WG. Statin use and outcome after intracerebral hemorrhage: case-control study and meta-analysis. Neurology. 2011;77:2073; author reply 2073-2073; author reply 2074.
63. Egger M, Davey Smoth G, Altman DG, Ed. Systematic reviews in healthcare: meta-analysis in context. London, UK: BMJ Publishing Group; 2001: 211-227
64. Posthuma WF, Westendorp RG, Vandenbroucke JP. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ. 1994;308:1268-1269.
65. Restrepo L, Bang OY, Ovbiagele B, Ali L, Kim D, Liebeskind DS, et al. Impact of hyperlipidemia and statins on ischemic stroke outcomes after intra-arterial fibrinolysis and percutaneous mechanical embolectomy. Cerebrovasc Dis. 2009;28:384-390.
66. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363: 757-767.
67. Flint AC, Kamel H, Navi BB, Rao VA, Faigeles BS, Conell C, et al. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke. 2012;43:147-154.
68. Flint AC, Kamel H, Navi BB, Rao VA, Faigeles BS, Conell C, et al. Inpatient statin use predicts improved ischemic stroke discharge disposition. Neurology. 2012;78:1678-1683.
69. FDA Drug Safety Communication: Severe liver injury associated with the use of dronedarone (marketed as Multaq). Accessed 15.12.11 from http://www.fda.gov/drugs/drugsafety/ucm240011.htm
70. Turner JR, Durham TA. Integrated cardiac safety; assessment methodologies for noncardiac drugs in discovery, development and postmarketing surveillance. Chichester, UK: John Wiley & Sons; 2008: 269
71. Miner J, Hoffhines A. The discovery of aspirin's antithrombotic effects. Tex Heart Inst J. 2007;34:179-186.
72. Hoe Heo J (Principal Investigator). The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke: EUREKA. NCT01364220 ClinicalTrials.gov. Accessed 24.08.12 from the Stroke Center Clinical Trials Registry: http://www.strokecenter.org/trials/clinicalstudies/ the-effects-of-very-early-use-of-rosuvastatin-in-preventingrecurrence- of-ischemic-stroke
73. Elkind MS (Principal Investigator). NeuSTART II. Neuroprotection with Statin Therapy for Acute Recovery Trial (Neu START): A Phase 2 safety and pilot efficacy study of lovastatin for the treatment of acute ischemic stroke. Accessed 24.08.12 from the Stroke Center Clinical Trials Registry: http://www.strokecenter.org/trials/clinicalstudies/ neuroprotection-with-statin- therapy-for-acute-recovery-trial-neu-startaphase- 2-safety-and-pilot-efficacy- study-of-lovastatin-for-the-treatment- of-acute-ischemic-stroke-spotrias
74. Joan Montaner (Study Director). Stroke Treatment with Acute Reperfusion and Simvastatin. Accessed 31.10.12 at: http://www.clinicaltrials. gov/ct2/show/NCT01073007?term=simvastatin+stroke&rank=1